Is MGM-15 A Dangerous Kratom Compound?
- Harold Pierre, MD
- 4 days ago
- 10 min read
Key Takeaways:
MGM-15 is a semi-synthetic opioid compound made from kratom alkaloids. It is not natural kratom.
MGM-15 tablets binds to both mu and delta receptors with potency that exceeds 7-hydroxymitragynine and morphine.
These products are already being sold online in the United States as "research chemicals," but make no mistake: people are using and abusing them.
There is a serious risk of addiction, dependence, and potentially fatal overdose with MGM-15 products.
Why Trust This Article: I'm Dr. Harold Pierre, a board-certified anesthesiologist and addiction medicine specialist with over 27 years of experience. I treat patients struggling with opioid addiction daily, including those who became dependent on kratom and 7-OH products. This article is based on a peer-reviewed scientific report published in the journal Drug Testing and Analysis in 2025, along with my direct clinical observations.
I Warned You About 7-OH. Now There's Something Worse.
In my previous article on 7-OH and kratom, I didn't sugarcoat things. I revealed that 7-hydroxymitragynine was being isolated from the kratom plant, concentrated in a lab, and sold as a "natural" supplement. I revealed that people were getting addicted and dying.
Now there's a new compound on the market that takes this even further. It's called MGM-15, and it's a direct derivative of 7-hydroxymitragynine, the same dangerous compound I've been warning people about. But MGM-15 is even more potent than 7-OH.
Every day in my clinic, I see patients who started with kratom and ended up addicted to concentrated 7-OH products. Interestingly enough, when Oklahoma made some kratom products illegal, patients began appearing to my clinic addicted to MGM-15. It's only a matter of time before I start seeing more and more patients addicted to MGM-15 tablets. In fact, based on what the research tells us, the addiction potential of this compound may be even worse than 7-OH.
What Exactly Is MGM-15?
Let me be very clear from the start: MGM-15 is not kratom. It is not an extract. It is not a natural product. MGM-15 is a semi-synthetic indole alkaloid that was originally created in a medicinal chemistry laboratory. Scientists took mitragynine (the primary naturally occurring alkaloid found in kratom (Mitragyna speciosa) leaves) and chemically modified it through several steps. First, mitragynine is converted to 7-hydroxymitragynine (7-OH). Then, 7-OH is further chemically altered to produce MGM-15 and its fluorinated cousin, MGM-16.
The goal of this research? To create orally active opioid agonists for pain management. These compounds could be swallowed in tablet form and still produce powerful effects at opioid receptors in the brain. This was originally done as part of legitimate pain research. The discovery was published by Matsumoto and colleagues in the Journal of Pharmacology and Experimental Therapeutics in 2014.
But here's the problem: what was developed as a research tool for understanding opioid receptor activation has now escaped the lab. By 2025, MGM-15 appeared in online vendor listings in the United States, sold as high-purity powder or pre-metered tablets. This is basically history repeating itself. Remember, morphine was extracted from opium. Heroin was synthesized from morphine. 7-OH was synthesized from mitragynine. And now MGM-15 has been synthesized from 7-OH. The pattern is clear: history repeats itself and if that is the case here, we can expect MGM-15 to spread through the population.
How Does MGM-15 Work in the Brain?
MGM-15 is what we call a dual mu/delta opioid receptor agonist. Let me explain what that means.
Most opioids (morphine, oxycodone, fentanyl, heroin) primarily target the mu-opioid receptor in the brain. That's the receptor responsible for pain relief, euphoria, respiratory depression, and addiction. When a drug activates this receptor, you feel "high" also known as euphoria. However, the mu receptor also controls brerathing. The more you activate this receptor, the more likely you are to stop breathing. This is why opioid overdose is so dangerous.
MGM-15 does this. But it also targets the delta opioid receptor with high affinity (binding). The delta receptor is involved in pain modulation, mood regulation, and reward. Activating both receptors simultaneously means MGM-15 produces a powerful, multi-layered opioid effect that may feel different from typical opioids. I believe this makes MGM-15 more addictive than typical opioids.
Here's the binding data from published research:
Compound | Mu-Opioid Receptor Affinity (Ki) | Delta-Opioid Receptor Affinity (Ki) | Potency vs. Morphine |
Mitragynine | Moderate (micromolar range) | Weak | Much weaker |
7-Hydroxymitragynine (7-OH) | High (nanomolar range) | Weak | ~10-15x stronger |
MGM-15 | Very High (~28 nM) | High (~59 nM) | Significantly stronger |
MGM-16 (fluorinated) | Extremely High (~2.1 nM) | Very High (~7 nM) | ~71-200x stronger |
Morphine | Reference standard | Weak | 1x (baseline) |
Look at that table carefully. MGM-15 has nanomolar affinity at both the mu and delta opioid receptors. That means it binds tightly and activates these receptors at extremely low doses. Its selective binding activity and potent signal at these receptors make it a powerful analgesic (pain medication), but also a powerful driver of addiction.
MGM-15 is orally active. In animal studies, it produced potent pain relief when given by mouth. That means unlike some research compounds that only work when injected, the MGM-15 tablet works when you swallow it. That's exactly why it's attractive to both legitimate researchers and to people looking to sell a new opioid product. With MGM-15, you don't have to inject it or smoke it. You can just swallow it. So, expect fake oxycodone pills, gummies, etc. It's coming!
From Kratom to Semi-Synthetic Opioids: How Did We Get Here?
I've said this before and I'll say it again: the story of kratom to 7-OH to MGM-15 is the same story as opium to morphine to heroin.
Here's the pattern:
Start with a plant. Kratom (Mitragyna speciosa) has been chewed as fresh leaf in Southeast Asia for centuries. In that form, exposure to potent opioid alkaloids is minimal. The leaf contains mostly mitragynine, and 7-hydroxymitragynine makes up less than 0.05% of the alkaloid content. Traditional users were not getting "high" in the way we think of it.
Isolate the active compound. Chemists figured out that mitragynine was the active ingredient. They figured out that 7-OH was more powerful than mitragynine and could be converted to 7-OH. So they started producing concentrated 7-OH products (tablets, gummies, liquid extracts, nasal sprays) and selling them as "kratom products."
Engineer something even stronger. That's MGM-15. By modifying the molecular formula of 7-OH, researchers created a compound with even greater potency and opioid receptor binding. And now it's for sale.
This is exactly what happened with opium. People used the plant for thousands of years. Then morphine was isolated. Then heroin was synthesized from morphine. Each step was marketed as "safer" or "better." Each step created more addiction, more overdoses, and more death.
The researchers who published the 2025 review article in Drug Testing and Analysis (Gour and colleagues) are sounding the alarm. They identified MGM-15 appearing in online vendor listings, sold as "research-only" material with disclaimers saying "not for human consumption." Sound familiar? That's the same language used to sell synthetic cannabinoids (Spice, K2) and bath salts before they were banned.
What Do MGM-15 Products Actually Look Like?
Based on the marketplace analysis in the 2025 report, MGM-15 products are being sold in the United States as:
High-purity powder (97-99% purity), in packages ranging from 250 mg to multi-gram lots
Pre-metered tablets containing approximately 12 mg per unit dose
Flavored liquid formulations at premium prices
Many of these products are listed under "7-hydroxymitragynine" categories on vendor websites. The manufacturer label may or may not accurately describe the formulation and composition. Some list certificates of analysis. Some don't.
The key point is this: when you buy an MGM-15 tablet, you have no idea what you're really getting. There is no FDA oversight. There is no standard for production. There is no quality control. You are trusting a manufacturer with zero accountability to give you a consistent, safe product. And we already know from the kratom and 7-OH markets that label accuracy is terrible. If someone dies from using it, the company will claim they are not liable because the package stated "not for human consumption."
The Addiction Risk Is Real
I don't need to speculate about whether MGM-15 causes addiction. The pharmacology tells us everything we need to know.
Any compound that:
Acts as a full agonist at the mu-opioid receptor
Has nanomolar binding affinity
Is orally active
Produces potent pain relief in animal models
...will cause tolerance, physical dependence, and withdrawal. That is the definition of an opioid. Period.
If you've read my article on why some people get addicted to kratom and others don't, you know that genetics play a role. Your liver enzymes (CYP3A4, CYP2D6) and your opioid receptor sensitivity determine how strongly you respond to these compounds. But with MGM-15, that biological lottery matters even less, because the compound is already in its most potent form. There's no metabolic conversion needed. The MGM-15 tablet delivers the active ingredients directly.
That's like skipping past the opium poppy and going straight to fentanyl.
What the 2025 Research Article Tells Us
The peer-reviewed article, titled "From Kratom to Semi-Synthetic Opioids: The Rise and Risks of MGM-15" and published in Drug Testing and Analysis (Gour et al., 2025), is one of the first comprehensive reviews of MGM-15 to appear in the scientific literature. Here's what the researchers found:
MGM-15 preserves the 7-OH indoloquinolizine core but differs in substitution from MGM-16 (which carries a 9-fluoro group). MGM-15 is the non-fluorinated analogue, making it synthetically simpler and more scalable, which likely explains why it's the one showing up in consumer markets.
In lab assays, MGM-15 suppresses electrically evoked contractions in a naltrexone-reversible manner. That's the hallmark test for opioid activity: if naltrexone (an opioid blocker) reverses the effect, the drug is acting as an opioid. MGM-15 passes that test clearly.
In animal studies, MGM-15 is orally active and produces potent pain relief. While less potent than MGM-16, it is still a highly active compound that exceeds the potency of 7-OH at the opioid receptor.
Compared to 7-OH, MGM-15 demonstrates higher mu/delta affinity and greater antinociceptive potency (pain-relieving strength) while retaining oral activity.
The researchers explicitly called for preemptive regulatory action against MGM-15.
How MGM-15 Compares to Other Kratom Derivatives
To put this in perspective, here's how the progression from natural kratom leaf to MGM-15 looks:
Product | Source | Opioid Receptor Activity | Risk Level |
Fresh kratom leaf | Natural plant | Mild (mostly mitragynine, trace 7-OH) | Lower (traditional use) |
Kratom extract | Concentrated plant | Moderate (enriched mitragynine) | Moderate |
7-OH products (tablets, gummies) | Semi-synthetic | High (potent mu-agonist) | High |
MGM-15 tablet | Semi-synthetic derivative | Very High (potent mu/delta dual agonist) | Very High |
MGM-16 | Semi-synthetic (fluorinated) | Extremely High (71-200x morphine) | Extreme |
Each step moves further from the natural plant and closer to a full-blown synthetic opioid. And each step brings more risk of addiction, overdose, and death.
The Legal Situation in the United States in 2025
Right now, the legal status of MGM-15 in the United States is murky, and that's by design.
Federally, MGM-15 is not yet listed under the Controlled Substances Act. It doesn't have a specific DEA scheduling. But here's the thing: the FDA has already recommended scheduling 7-hydroxymitragynine, and MGM-15 is a direct derivative of 7-OH. Any legal action against 7-OH could potentially sweep MGM-15 into the same regulatory net.
Some states have Kratom Consumer Protection Acts or analog drug laws that could apply to MGM-15. But enforcement is inconsistent, and the vendors know it.
The researchers behind the 2025 review article recommend:
Emergency, time-limited control of MGM-15 while permanent rulemaking evaluates its abuse potential
Narrowly drawn scheduling (Schedule II-style) focused on concentrated semi-synthetic preparations, not the natural leaf
Strengthened drug testing that routinely includes 7-OH, mitragynine pseudoindoxyl, and now MGM-15 in both clinical and forensic toxicology panels
I agree with all of these recommendations. But I also know that regulation moves slowly, and people are being harmed right now.
How Can You Protect Yourself?
If you encounter anything labeled as MGM-15, walk away. Here's what you need to know:
Don't trust "not for human consumption" labels. That's a legal trick, not a safety measure. It allows the manufacturer to sell the product without FDA oversight and provides them with legal protection if someone dies from using it.
Don't assume it's "just kratom." MGM-15 is as far from a kratom leaf as heroin is from an opium poppy.
If you're currently using kratom or 7-OH products, be aware that your tolerance may lead you toward these more potent compounds. That escalation is exactly how addiction works.
Frequently Asked Questions
What is MGM-15?
MGM-15 is a semi-synthetic opioid compound derived from 7-hydroxymitragynine, which itself is a potent alkaloid found in kratom. It was originally developed in a medicinal chemistry lab as a research tool for studying opioid receptors. It is now being sold online in the United States as a "research chemical" in tablet and powder form.
Is the MGM-15 tablet the same as kratom?
No. MGM-15 is not kratom. Kratom is a natural botanical leaf from the Mitragyna speciosa plant. MGM-15 is a lab-engineered semi-synthetic derivative that has been chemically modified to increase opioid receptor potency. Calling MGM-15 a "kratom product" is like calling heroin a "poppy product": technically connected, but fundamentally different.
How potent is MGM-15 compared to morphine?
MGM-15 has significantly greater opioid receptor binding affinity than morphine. In animal studies, it demonstrates potent oral analgesic activity that exceeds both 7-hydroxymitragynine and morphine. Its dual action at both mu and delta opioid receptors makes it a particularly potent compound.
Can MGM-15 cause addiction?
Yes. Any compound that acts as a potent agonist at the mu-opioid receptor will cause tolerance, physical dependence, and withdrawal with regular use. The pharmacological profile of MGM-15 (high affinity, full agonism, oral activity) is the textbook definition of an addictive opioid.
Are MGM-15 products legal?
The legal status varies. MGM-15 is not currently scheduled under the federal Controlled Substances Act, but the FDA's recommendation to schedule 7-OH could affect MGM-15 as well. Some states may classify it under analog drug laws. The fact that it's "legal" does not mean it's safe.
What should I do if I'm addicted to kratom or MGM-15?
Seek professional help. Medications like buprenorphine (Suboxone) can treat the withdrawal and cravings safely. You can schedule an appointment with us, or call 918-518-1636.
References
Gour A et al. 2025, September 11. From kratom to semi-synthetic opioids: the rise and risks of MGM-15. Drug Testing and Analysis. Epub ahead of print. https://doi.org/10.1002/dta.3952
Matsumoto K et al. 2014. Orally active opioid μ/δ dual agonist MGM-16, a derivative of the indole alkaloid mitragynine, exhibits potent antiallodynic effect on neuropathic pain in mice. Journal of Pharmacology and Experimental Therapeutics. 348(3):383–392. https://doi.org/10.1124/jpet.113.208108
Alsbrook S, Pro G, Koturbash I. 2025. From kratom to 7-hydroxymitragynine: evolution of a natural remedy into a public-health threat. Pharmaceutical Biology. 63(1):896–911. https://doi.org/10.1080/13880209.2025.2590311
US Food and Drug Administration. 2025. Technical assessment of 7-hydroxymitragynine-containing products. Silver Spring, MD. https://www.fda.gov/media/187899/download
Harold Pierre, MD, is a board-certified anesthesiologist, board-certified addiction medicine specialist, and a concierge addiction doctor based out of Tulsa, Oklahoma with over 27 years of experience. He is board-certified by the American Board of Anesthesiology and the American Board of Preventive Medicine. He is licensed in Florida, Texas, Oklahoma, Louisiana, and Arizona. If you are seeking care, you may schedule an appointment with him by calling or texting 918-518-1636. LinkedIn
Disclaimer: This blog post is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of your doctor or other qualified health provider with any questions you may have regarding your health or a medical condition before making any changes. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Comments